| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a2b2c13638e198ec3ca3d49d181123 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1688 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2014-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6632639fea9d897fb43c4daf3892f3af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5002603a9f52537ea321ab09b13521d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc308c7ba239e6be19ea43db52899a7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f656ba3e5d56b77a8d154ad0e5bd51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efa10e67dbb23a9b88fd03128e5508ea |
| publicationDate |
2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-368036-B |
| titleOfInvention |
INHALABLE PARTICLES INCLUDING THYOTROPE AND INDACATEROL. |
| abstract |
The present invention relates to inhalable particles comprising an intimate mixture consisting of a) an amorphous tiotropium compound, b) an amorphous indacaterol compound and c) a sugar derivative, in which the weight of the sugar derivative ranges from 0 to 85% with respect to the weight of the inhalable particles. It also refers to a pharmaceutical composition comprising the inhalable particles of the invention, a process for their preparation and their use in the treatment of asthma or chronic obstructive pulmonary disease (COPD). |
| priorityDate |
2013-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |